Free Trial
NASDAQ:DRTS

Alpha Tau Medical Q4 2023 Earnings Report

Alpha Tau Medical logo
$3.27 +0.14 (+4.47%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$3.22 -0.04 (-1.38%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alpha Tau Medical EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.13
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Alpha Tau Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alpha Tau Medical Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Alpha Tau Medical's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Alpha Tau Medical Earnings Headlines

Alpha Tau Medical Ltd. (DRTS) - Yahoo Finance
Critical AI announcement set to ignite AI 2.0
Markets are jittery. Rallies fade. Sectors rotate overnight. And the true impact of new tariffs and policy shifts hasn’t even hit the data yet. That’s why smart traders are turning to a strategy built for exactly this kind of market—fast, simple, and designed to react to real price action, not predictions.
See More Alpha Tau Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email.

About Alpha Tau Medical

Alpha Tau Medical (NASDAQ:DRTS), a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

View Alpha Tau Medical Profile

More Earnings Resources from MarketBeat